All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld MedTech Perspectives » Fee diversion alive and well in H.R. 1249

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Patent

Fee diversion alive and well in H.R. 1249

June 22, 2011
By Mark McCarty
No Comments

Those with a keen eye trained on the patent reform bill now under consideration in the House of Representatives might universally hold a dim view of fee diversion even if they see first-to-file and the prior user defense through profoundly different lenses. The problem is that the manager's mark for H.R. 1249 as of June 20 includes language that will put the fees paid by patent, trademark and copyright applicants right back into the hands of appropriators, who will have a tough time avoiding the urge to raid the cookie jar in a fiscal environment in which cookies are increasingly scarce.

The newest iteration of H.R. 1249 includes the language, “there is established in the Treasury a Patent and Trademark Fee Reserve Fund,” which will be filled with the proceeds collected in excess of the amounts appropriated to the U.S. Patent and Trademark Office in a given fiscal year. This new feature of H.R. 1249 provides that the monies in question “shall be made available until expended only for obligation and expenditure by” PTO “to the extent and in the amounts provided in appropriations Acts.”

So as the saying goes, the Appropriator giveth and the Appropriator taketh away. Or as some on Capitol Hill like to say, “there are legislators and then there are appropriators.”

It's not hard to understand why the House Appropriations Committee wants to avoid the appearance of favoritism, but the conceptual construct underlying the idea of ending diversion of PTO's fees into the Treasury's general fund is that innovation creates job and PTO needs more money to clear the patent backlog, which is presumed to be chock-full of job-creating innovation. Therefore, you have to let PTO keep the fees it collects from inventors if you want intellectual property to play a meaningful role in bringing the economy back to life. I have not heard the argument that the $50 million the Treasury would lose to PTO would be at least offset by an increase in tax revenues, but any such effect might not be felt for a couple of years, which might seem like an eternity to those trying to keep the U.S. government from ending up with the kind of credit rating now enjoyed by Greece and Ireland.

Still, the casual observer has to wonder how many small cuts to the corpus will yield a corpse. First-to-file is not universally popular, and the purportedly offsetting prior user defense is obnoxious to a far greater number. Is there any need for this bill if it allows appropriators to dive into the PTO piggy bank any time they want?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing